Archive for the ‘clinical study retractions’ Category
A pharmacology researcher at Ohio State University has added his seventh retraction, four years after a finding of misconduct by the U.S. Office of Integrity (ORI).
falsified and/or fabricated Western blots in eighteen (18) figures and in six (6) published papers.
In 2012, the ORI finding, which resulted in a three-year funding ban (that is now complete), recommended that Elton retract all six papers, one of which had already been retracted at the time of the report.
Four years later, the last of the six papers flagged by the ORI has finally been retracted by Molecular and Cellular Endocrinology.
Here’s a strange one: We discovered a paper about an antibiotic-resistant strain of bacteria that bore two retraction notices, and each provided a different reason for retraction. One alleged misconduct; that notice still appears now. The other — which has since disappeared — said the paper was submitted by mistake.
“In vitro effect of boric acid and calcium fructoborate esters against methicillinresistant Staphylococcus aureus strain” was published in the South-Western Journal of Horticulture, Biology and Environment. The full text isn’t available on the journal’s website.
How is that possible? A spokesperson for Springer told us that they have reason to believe a third-party company may have helped prepare the papers for publication, and in the process might have spread the material around to multiple manuscripts.
The details of the cluster are a bit perplexing, so bear with us. Two of the papers — that were published only months apart — have already been retracted, as we reported in April. Now, two other papers have been retracted from Molecular Biology Reports — and both notices cite the previously retracted papers. The new notices also say that there’s reason to believe that the peer-review process was compromised.
All papers conclude that a certain polymorphism could signal a risk for coronary artery disease among Chinese people.
We’ll start with the retraction notice for “Fibroblast growth factor receptor 4 polymorphisms and coronary artery disease: a case control study,” which cites the two papers that were retracted previously:
A journal has retracted the results of a clinical trial comparing strategies for bladder tumors after the authors mischaracterized the way patients were assigned to each procedure.
In addition, the journal European Urology has pulled a string of correspondence between author Harry Herr at Memorial Sloan Kettering Cancer Center and an outside expert, who had questioned aspects of the study totally unrelated to the methodology, such as its generalizability.
They’re now retracting the paper, from Molecular Medicine Reports, because it originally reported that higher concentrations of retinoic acid (RA) were more effective in curbing the proliferation of brain tumor cells. But it seems that the RA dose made less of a difference than they originally believed, according to the retraction notice:
A tribunal in the UK has rejected an appeal by Queen Mary University of London, who sought to reverse a previous order that they release data from a controversial 2011 paper in The Lancet about chronic fatigue syndrome (CFS).
The decision is one in a long series of judgments about the so-called PACE trial, which reported that two treatments — known as cognitive behavioral therapy and graded exercise therapy — helped alleviate the symptoms of the condition. But ever since The Lancet article and follow-up papers have been published, patients and critics have questioned the conclusions and clamored to see the raw data.
The main criticisms: The findings may prompt some to believe chronic fatigue is a mental, not a physical, disorder, and the PACE program could actually be harmful to patients by encouraging too much exercise. These criticisms were recently bolstered by a re-analysis of the evidence by the Agency for Healthcare Research and Quality, which downgraded its original conclusions about the effectiveness of cognitive behavioral therapy and graded exercise therapy.
In March 2014, Read the rest of this entry »
The retraction notice, issued by Advances in Human Biology (AIHB) in June, recognizes the case as “scientific misconduct.” The journal launched an investigation after the plagiarism was flagged by the author of the original report, the editor-in-chief of the journal told us. Eventually, the journal retracted the report — and removed it entirely from their website.
Federal judges in Ohio have dismissed two lawsuits claiming that university researchers used false results to secure more than $250 million in federal grants.
Both lawsuits, which objected to a study examining the effects of CrossFit-based training, were filed by Mitchell Potterf, the owner of a gym affiliated with CrossFit in Columbus, Ohio. Potterf took issue with a 2013 study by researchers at Ohio State University (OSU) that was conducted at his gym.
Potterf filed one suit against the OSU researchers and a second against the National Strength and Conditioning Association (NCSA). The NSCA publishes the Journal of Strength and Conditioning Research, where a paper about the study appeared. The article, “Crossfit-based high-intensity power training improves maximal aerobic fitness and body composition,” has been cited 15 times, according to Thomson Reuters Web of Science.
The study followed 43 men and women as they completed 10 weeks of CrossFit-based training. In addition to those 43 participants, 11 dropped out before completing the regimen. According to the original paper: Read the rest of this entry »
PLOS ONE has retracted three papers after the first author admitted to submitting the manuscripts without co-authors’ consent, and an investigation suggested that two out of the three papers had received faked reviews.
Last August, the same author — Lishan Wang of the Shanghai Jiao Tong University — lost two more papers (one in Tumor Biology and the other in Gene), also after the peer review process was found to be compromised. All five papers — which share other authors in common — were originally published in 2013, and four list Wang as the first author. The retractions follow an investigation by Shanghai Jiao Tong University.
A researcher banned from funding by a Canadian agency for misconduct has earned her second retraction, after a reanalysis uncovered problems with the paper’s conclusions.
The retraction follows an investigation by Sophie Jamal‘s former workplace, the Women’s College Hospital in Toronto, which has led to a recent retraction of a JAMA paper due to data manipulation, and a lifetime funding ban from the Canadian Institutes of Health Research (CIHR).
The latest retraction stemmed from a re-analysis of the paper by the Canadian Multicentre Osteoporosis Study Group, of which the paper was a part; all authors but Jamal have requested the retraction. In the notice, the authors say that they believe no patients were harmed as a result of the “possibly invalid conclusions” in the paper, which showed patients with kidney problems were at higher risk of bone loss. A researcher told us a third paper by Jamal is also due to be retracted soon.